Wed, Jun 18, 2025
[Archive]
Volume 11, Issue 42 (Mar 2003)
J Adv Med Biomed Res 2003, 11(42): 31-37 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Marashinezhad S A, Bassampour S A. The Use Of Bioglass In The Treatment Of Benign Bone Tumors And Nonunion Bone Fractures After Surgery. J Adv Med Biomed Res 2003; 11 (42) :31-37
URL: http://journal.zums.ac.ir/article-1-23-en.html
URL: http://journal.zums.ac.ir/article-1-23-en.html
The Use Of Bioglass In The Treatment Of Benign Bone Tumors And Nonunion Bone Fractures After Surgery
Abstract: (156620 Views)
Introduction: Bone grafting has been recommended in various clinical problems such as nonunion fractures after surgery, fixation of fractures, filling remaining cavities in bones after debridement and curtage in osteomyelitis and tumors. The use of Bioglass material are recommended by manufacturers when bone grafting is not possible. In this investigation, the use of Nova bone (Bioglass) was studied on the treatment of benign tumors and nonunion fractures after surgery.
Materials and Methods: In this case series study 14 patients with bone tumors and 2 patients with nonunion fracture were studied over one year period. All bone tumors were benign and consisted of 3 cases of nonossifying fibroma (N.O.F), 3 cases of anurismal bone cyst (A.B.C.), 2 cases of unicameral bone cyst (U.B.C), one case of ossifying fibroma and 5 cases of giant call tumors (G.C.T).
Results: Unpredictable clinical complications were not seen in any of the cases. The average recovery time for benign tumors after nova bone grafting was 3 months and for nonunion fractures was 6 months. Recurrence were occurred in all cases of giant cell tumors.
Conclusion: Nova bone is appropriate for use in benign tumors of bone, but we do not recommend it in the treatment of patients with malignant or sometimes malignant tumors of bone such as giant cell tumors.
Materials and Methods: In this case series study 14 patients with bone tumors and 2 patients with nonunion fracture were studied over one year period. All bone tumors were benign and consisted of 3 cases of nonossifying fibroma (N.O.F), 3 cases of anurismal bone cyst (A.B.C.), 2 cases of unicameral bone cyst (U.B.C), one case of ossifying fibroma and 5 cases of giant call tumors (G.C.T).
Results: Unpredictable clinical complications were not seen in any of the cases. The average recovery time for benign tumors after nova bone grafting was 3 months and for nonunion fractures was 6 months. Recurrence were occurred in all cases of giant cell tumors.
Conclusion: Nova bone is appropriate for use in benign tumors of bone, but we do not recommend it in the treatment of patients with malignant or sometimes malignant tumors of bone such as giant cell tumors.
Type of Study: Original Research Article |
Received: 2006/09/6 | Accepted: 2017/06/18 | Published: 2017/06/18
Received: 2006/09/6 | Accepted: 2017/06/18 | Published: 2017/06/18
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright Policy
